FASTK

Summary

FASTK (Fas activated serine/threonine kinase, HGNC:24676) is a protein-coding gene on chromosome 7q36.1, encoding Fas-activated serine/threonine kinase (Q14296). Phosphorylates the splicing regulator TIA1, thereby promoting the inclusion of FAS exon 6, which leads to an mRNA encoding a pro-apoptotic form of the receptor.

The protein encoded by this gene is a member of the serine/threonine protein kinase family. This kinase was shown to be activated rapidly during Fas-mediated apoptosis in Jurkat cells. In response to Fas receptor ligation, it phosphorylates TIA1, an apoptosis-promoting nuclear RNA-binding protein. The encoded protein is a strong inducer of lymphocyte apoptosis. Two transcript variants encoding different isoforms have been found for this gene. Other variants exist, but their full-length natures have not yet been determined.

Source: NCBI Gene 10922 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 81 total
• Druggable target: yes
• MANE Select transcript: NM_006712

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24676
Approved symbol	FASTK
Name	Fas activated serine/threonine kinase
Location	7q36.1
Locus type	gene with protein product
Status	Approved
Aliases	FAST
Ensembl gene	ENSG00000164896
Ensembl biotype	protein_coding
OMIM	606965
Entrez	10922

Gene structure

Transcript identifiers

Ensembl transcripts: 33 — 20 protein_coding, 9 retained_intron, 4 protein_coding_CDS_not_defined

ENST00000297532, ENST00000353841, ENST00000459800, ENST00000460980, ENST00000461979, ENST00000465272, ENST00000466855, ENST00000467237, ENST00000469237, ENST00000478477, ENST00000478883, ENST00000482571, ENST00000482806, ENST00000483953, ENST00000489884, ENST00000496663, ENST00000899741, ENST00000899742, ENST00000899743, ENST00000899744, ENST00000899745, ENST00000899746, ENST00000899747, ENST00000899748, ENST00000899749, ENST00000899750, ENST00000899751, ENST00000914251, ENST00000959426, ENST00000959427, ENST00000959428, ENST00000959429, ENST00000959430

RefSeq mRNA: 3 — MANE Select: NM_006712 NM_001258461, NM_006712, NM_033015

CCDS: CCDS59088, CCDS5918, CCDS5919

Canonical transcript exons

ENST00000297532 — 10 exons

Exon	Start	End
ENSE00001831355	151080685	151080809
ENSE00003476596	151078562	151078701
ENSE00003485520	151077879	151078092
ENSE00003488016	151078842	151079021
ENSE00003497632	151077310	151077401
ENSE00003532150	151076913	151077027
ENSE00003610790	151077621	151077780
ENSE00003634419	151077101	151077236
ENSE00003727154	151079500	151079922
ENSE00003844475	151076624	151076832

Expression profiles

Bgee: expression breadth ubiquitous, 276 present calls, max score 98.33.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 30.1617 / max 169.5902, expressed in 1818 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
86860	25.7215	1814
86861	3.4465	1638
86862	0.8538	590
86859	0.1399	47

Top tissues by expression

300 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	98.33	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.91	gold quality
right hemisphere of cerebellum	UBERON:0014890	97.68	gold quality
mucosa of transverse colon	UBERON:0004991	97.56	gold quality
adenohypophysis	UBERON:0002196	97.55	gold quality
cerebellar hemisphere	UBERON:0002245	97.34	gold quality
cerebellar cortex	UBERON:0002129	97.17	gold quality
metanephros cortex	UBERON:0010533	97.16	gold quality
gastrocnemius	UBERON:0001388	97.07	gold quality
lower esophagus mucosa	UBERON:0035834	97.07	gold quality
right lobe of thyroid gland	UBERON:0001119	96.99	gold quality
right uterine tube	UBERON:0001302	96.83	gold quality
right lobe of liver	UBERON:0001114	96.57	gold quality
transverse colon	UBERON:0001157	96.46	gold quality
small intestine Peyer’s patch	UBERON:0003454	96.46	gold quality
left lobe of thyroid gland	UBERON:0001120	96.45	gold quality
granulocyte	CL:0000094	96.42	gold quality
left ovary	UBERON:0002119	96.35	gold quality
pituitary gland	UBERON:0000007	96.34	gold quality
muscle of leg	UBERON:0001383	96.34	gold quality
right ovary	UBERON:0002118	96.33	gold quality
body of uterus	UBERON:0009853	96.15	gold quality
left uterine tube	UBERON:0001303	96.09	gold quality
endocervix	UBERON:0000458	96.08	gold quality
right atrium auricular region	UBERON:0006631	96.07	gold quality
right frontal lobe	UBERON:0002810	96.05	gold quality
muscle layer of sigmoid colon	UBERON:0035805	96.03	gold quality
body of stomach	UBERON:0001161	95.92	gold quality
right adrenal gland	UBERON:0001233	95.84	gold quality
ectocervix	UBERON:0012249	95.77	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.59

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOXC1, MEF2A, MYF5, MYOD1, NFATC1, NFATC3, PRDM1, SSRP1, TCF3

miRNA regulators (miRDB)

26 targeting FASTK, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-519A-3P	99.67	71.67	1868
HSA-MIR-519B-3P	99.67	71.67	1868
HSA-MIR-519C-3P	99.67	71.67	1870
HSA-MIR-328-5P	99.08	64.65	1000
HSA-MIR-6885-5P	98.71	64.33	902
HSA-MIR-12120	98.05	68.44	1768

Literature-anchored findings (GeneRIF, showing 8)

• FAST is a survival protein that senses mitochondrial stress and modulates TIA-1 regulated changes in protein expression. (PMID:15572676)
• FAST K synergizes with TIA-1/TIAR proteins to regulate Fas alternative splicing (PMID:17135269)
• Nuclear FAST can regulate the splicing of FGFR2 transcripts. (PMID:17592127)
• FAST expression on lung cells of hematopoietic origin is crucial in mediating lipopolysaccharide-induced neutrophil migration to the lung in transgenic FAST-deficient mice compared with wild type controls. (PMID:20363972)
• MIR-106a-5p functions as a tumor suppressor during the development of astrocytomas by targeting FASTK. (PMID:24013584)
• FASTK binds at multiple sites along the ND6 mRNA and its precursors and cooperates with the mitochondrial degradosome to ensure regulated ND6 mRNA biogenesis. (PMID:25704814)
• Systematic Analysis of FASTK Gene Family Alterations in Cancer. (PMID:34768773)
• Accuracy of FAST in detecting intraabdominal bleeding in major trauma with pelvic and/or acetabular fractures: a retrospective cohort study. (PMID:38253932)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	fastk	ENSDARG00000077075
mus_musculus	Fastk	ENSMUSG00000028959
rattus_norvegicus	Fastk	ENSRNOG00000011667

Paralogs (5): FASTKD2 (ENSG00000118246), FASTKD3 (ENSG00000124279), TBRG4 (ENSG00000136270), FASTKD1 (ENSG00000138399), FASTKD5 (ENSG00000215251)

Protein

Protein identifiers

Fas-activated serine/threonine kinase — Q14296 (reviewed: Q14296)

All UniProt accessions (3): A0A090N8I0, A0A090N8Z7, Q14296

UniProt curated annotations — full annotation on UniProt →

Function. Phosphorylates the splicing regulator TIA1, thereby promoting the inclusion of FAS exon 6, which leads to an mRNA encoding a pro-apoptotic form of the receptor. Required for the biogenesis of some mitochondrial-encoded mRNAs, specifically stabilizes ND6 (NADH dehydrogenase complex subunit 6) mRNA, and regulates its levels.

Subunit / interactions. Interacts with TIA1; the interactions leads to TIA1 phosphorylation. Interacts with TIAR.

Subcellular location. Mitochondrion matrix.

Tissue specificity. Expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.

Post-translational modifications. Autophosphorylated on serine/threonine residues. Activated by dephosphorylation.

Domain organisation. The RAP domain is essential for RNA-binding.

Similarity. Belongs to the FAST protein kinase family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q14296-1	1	yes
Q14296-2	2
Q14296-3	3
Q14296-4	4

RefSeq proteins (3): NP_001245390, NP_006703, NP_148936 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR010622	FAST_Leu-rich	Domain
IPR013579	FAST_2	Domain
IPR013584	RAP	Domain
IPR050870	FAST_kinase	Family

Pfam: PF06743, PF08368, PF08373

Enzyme classification (BRENDA):

• EC 2.7.11.8 — Fas-activated serine/threonine kinase (BRENDA: 2 organisms, 11 substrates, 3 inhibitors, 0 Km, 0 kcat entries)

Catalyzed reactions (Rhea), 4 shown:

• L-seryl-[Fas-activated protein] + ATP = O-phospho-L-seryl-[Fas-activated protein] + ADP + H(+) (RHEA:15881)
• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)
• L-threonyl-[Fas-activated protein] + ATP = O-phospho-L-threonyl-[Fas-activated protein] + ADP + H(+) (RHEA:53920)

UniProt features (10 total): splice variant 4, sequence variant 2, chain 1, domain 1, region of interest 1, mutagenesis site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14296-F1	74.88	0.38

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (1):

Position	Phenotype
35	abolishes isoform 4 expression.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9837092	FASTK family proteins regulate processing and stability of mitochondrial RNAs

MSigDB gene sets: 154 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, CHIBA_RESPONSE_TO_TSA_UP, GOBP_REGULATION_OF_MRNA_CATABOLIC_PROCESS, TGCACTT_MIR519C_MIR519B_MIR519A, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, PATIL_LIVER_CANCER, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, GOBP_APOPTOTIC_SIGNALING_PATHWAY, GOBP_REGULATION_OF_CATABOLIC_PROCESS, YY1_02, GOBP_MITOCHONDRIAL_RNA_PROCESSING, ZIC1_01, GOBP_RNA_SPLICING, GOBP_MITOCHONDRIAL_RNA_METABOLIC_PROCESS

GO Biological Process (6): mitochondrial RNA processing (GO:0000963), protein phosphorylation (GO:0006468), regulation of RNA splicing (GO:0043484), regulation of mitochondrial mRNA stability (GO:0044528), apoptotic signaling pathway (GO:0097190), apoptotic process (GO:0006915)

GO Molecular Function (9): RNA binding (GO:0003723), protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), Fas-activated serine/threonine kinase activity (GO:0033867), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (3): mitochondrion (GO:0005739), mitochondrial matrix (GO:0005759), ribonucleoprotein granule (GO:0035770)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Mitochondrial RNA degradation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
mitochondrion	2
protein kinase activity	2
mitochondrial RNA metabolic process	1
RNA processing	1
mitochondrial gene expression	1
phosphorylation	1
protein modification process	1
RNA splicing	1
regulation of gene expression	1
regulation of primary metabolic process	1
regulation of mRNA stability	1
apoptotic process	1
signal transduction	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
nucleic acid binding	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
protein serine/threonine kinase activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
cytoplasm	1
intracellular membrane-bounded organelle	1
intracellular organelle lumen	1
intracellular membraneless organelle	1
supramolecular complex	1

Protein interactions and networks

STRING

1308 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FASTK	FASTKD2	Q9NYY8	945
FASTK	FASTKD1	Q53R41	749
FASTK	TIA1	P31483	732
FASTK	TIAL1	Q01085	726
FASTK	MT-ND6	P03923	682
FASTK	GRSF1	Q12849	653
FASTK	FASTKD5	Q7L8L6	645
FASTK	EIF4E	P06730	616
FASTK	DDX28	Q9NUL7	536
FASTK	MTERF3	Q96E29	496
FASTK	XRN1	Q8IZH2	492
FASTK	RPUSD3	Q6P087	490
FASTK	CPEB1	Q9BZB8	479
FASTK	RPS6KA3	P51812	473
FASTK	RPUSD4	Q96CM3	469

IntAct

28 interactions, top by confidence:

A	B	Type	Score
WIPF1	FASTK	psi-mi:“MI:0915”(physical association)	0.560
FASTK	WIPF1	psi-mi:“MI:0915”(physical association)	0.560
PRPF31	FASTK	psi-mi:“MI:0915”(physical association)	0.560
ESRRG	FASTK	psi-mi:“MI:0915”(physical association)	0.560
FASTK	CHERP	psi-mi:“MI:0915”(physical association)	0.560
TOP3B	FASTK	psi-mi:“MI:0915”(physical association)	0.560
FASTK	ATN1	psi-mi:“MI:0915”(physical association)	0.560
KLK6	FASTK	psi-mi:“MI:0915”(physical association)	0.560
FASTK	TNKS2	psi-mi:“MI:0407”(direct interaction)	0.440
CRK	FASTK	psi-mi:“MI:0915”(physical association)	0.400
FASTK	HSP90AB1	psi-mi:“MI:0915”(physical association)	0.400
FASTK	CALCOCO2	psi-mi:“MI:0915”(physical association)	0.370
FASTK	TGM1	psi-mi:“MI:0914”(association)	0.350
LARP4B	IGF2BP3	psi-mi:“MI:0914”(association)	0.350
ESRRG	FASTK	psi-mi:“MI:0915”(physical association)	0.000
CHERP	FASTK	psi-mi:“MI:0915”(physical association)	0.000
TOP3B	FASTK	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (28): FASTK (Two-hybrid), FASTK (Two-hybrid), RBPMS (Two-hybrid), FASTK (Two-hybrid), FASTK (Affinity Capture-MS), FASTK (Two-hybrid), FASTK (Affinity Capture-RNA), FASTK (Affinity Capture-MS), FASTK (Two-hybrid), FASTK (Two-hybrid), ESRRG (Two-hybrid), FASTK (Reconstituted Complex), FASTK (Affinity Capture-Western), FASTK (Affinity Capture-MS), FASTK (Affinity Capture-MS)

ESM2 similar proteins: A4FU01, A4FUG7, A6NE52, D2HS90, D4A929, O15287, O94761, O95382, P0C025, P29473, P29474, P51617, P70313, P97270, Q05932, Q14296, Q15477, Q1JPD6, Q2LGB3, Q3MHT4, Q3U5Q7, Q3V1L6, Q562E7, Q5M8V2, Q5ND34, Q5PQ04, Q5RA67, Q5RAJ5, Q5XIS1, Q62406, Q69ZM6, Q6ZS72, Q6ZVH7, Q6ZVK8, Q75NR7, Q76MJ5, Q7M733, Q80UU1, Q8BLY7, Q8BTN6

Diamond homologs: Q14296, Q9JIX9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

81 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	52
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1272 predictions. Top by Δscore:

Variant	Effect	Δscore
7:151076830:TAG:T	acceptor_gain	1.0000
7:151076831:AG:A	acceptor_gain	1.0000
7:151076832:GC:G	acceptor_loss	1.0000
7:151076833:C:CC	acceptor_gain	1.0000
7:151076833:C:T	acceptor_loss	1.0000
7:151076834:T:C	acceptor_loss	1.0000
7:151076905:CCACT:C	donor_loss	1.0000
7:151076906:CACTC:C	donor_loss	1.0000
7:151076907:ACTCA:A	donor_loss	1.0000
7:151076908:CTCA:C	donor_loss	1.0000
7:151076909:TCACC:T	donor_loss	1.0000
7:151076910:CACC:C	donor_loss	1.0000
7:151076911:A:AC	donor_gain	1.0000
7:151076911:A:C	donor_loss	1.0000
7:151076912:C:CC	donor_gain	1.0000
7:151076912:C:CG	donor_loss	1.0000
7:151076912:CCGG:C	donor_gain	1.0000
7:151077023:CCACC:C	acceptor_gain	1.0000
7:151077024:CACC:C	acceptor_gain	1.0000
7:151077024:CACCC:C	acceptor_gain	1.0000
7:151077025:ACC:A	acceptor_gain	1.0000
7:151077025:ACCCT:A	acceptor_loss	1.0000
7:151077026:CC:C	acceptor_gain	1.0000
7:151077026:CCC:C	acceptor_gain	1.0000
7:151077027:CC:C	acceptor_gain	1.0000
7:151077027:CCT:C	acceptor_loss	1.0000
7:151077028:C:CC	acceptor_gain	1.0000
7:151077028:C:T	acceptor_gain	1.0000
7:151077028:CTGCA:C	acceptor_loss	1.0000
7:151077029:T:A	acceptor_loss	1.0000

AlphaMissense

3450 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:151077233:A:G	F432S	0.998
7:151077375:A:G	L409S	0.998
7:151077232:G:C	F432L	0.996
7:151077232:G:T	F432L	0.996
7:151077234:A:G	F432L	0.996
7:151077911:A:T	V336D	0.996
7:151076777:A:G	L533P	0.994
7:151076969:C:G	G496R	0.994
7:151077230:A:G	L433P	0.994
7:151077730:C:G	A364P	0.994
7:151078070:G:C	P283R	0.994
7:151077233:A:C	F432C	0.993
7:151077236:T:A	D431V	0.993
7:151077349:A:C	Y418D	0.993
7:151078058:A:G	L287P	0.993
7:151078656:G:T	A244D	0.993
7:151076968:C:T	G496D	0.992
7:151077967:G:C	N317K	0.992
7:151077967:G:T	N317K	0.992
7:151077971:A:T	V316D	0.991
7:151078070:G:T	P283H	0.991
7:151076968:C:A	G496V	0.990
7:151077227:A:T	L434Q	0.990
7:151077395:C:A	K402N	0.990
7:151077395:C:G	K402N	0.990
7:151077741:A:G	L360P	0.990
7:151076765:A:G	L537P	0.989
7:151076927:A:C	Y510D	0.989
7:151077379:C:G	G408R	0.989
7:151077379:C:T	G408R	0.989

dbSNP variants (sampled 300 via entrez): RS1000693573 (7:151080811 G>A), RS1001244461 (7:151080086 C>A,T), RS1001512726 (7:151080781 G>A,C), RS1001844773 (7:151079321 G>A,C), RS1003777174 (7:151082696 C>T), RS1003854900 (7:151080121 A>G), RS1004810846 (7:151081378 A>G,T), RS1005411788 (7:151080473 T>A,C), RS1005794719 (7:151080300 T>A), RS1005935445 (7:151078350 G>C), RS1006714174 (7:151081140 T>C), RS1006827873 (7:151079024 G>A), RS1007097750 (7:151081454 C>T), RS1007427806 (7:151077486 G>A,C), RS1008369509 (7:151080371 C>G,T)

Disease associations

OMIM: gene MIM:606965 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST003476_9	Eyebrow thickness	7.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6196088 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

3 potent at pChembl≥5 of 3 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.82	IC50	150	nM	CHEMBL6165181
6.77	IC50	170	nM	CHEMBL6168517
6.50	IC50	320	nM	CHEMBL6159585

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	3
Air Pollutants	affects cotreatment, increases abundance, increases expression, affects expression	2
Ozone	affects cotreatment, increases expression, increases abundance, affects expression	2
tert-Butylhydroperoxide	decreases expression	2
aristolochic acid I	decreases expression	1
4-oxoretinoic acid	decreases expression	1
testosterone enanthate	affects expression	1
alpha-pinene	increases expression, increases abundance, affects cotreatment	1
3,4-dihydroxyphenylethanol	increases expression	1
perfluorooctanoic acid	decreases expression	1
4-hydroxy-2-nonenal	decreases expression	1
methacrylaldehyde	affects cotreatment, increases expression, increases abundance	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
perfluorohexanesulfonic acid	decreases expression	1
Bortezomib	decreases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Temozolomide	decreases expression	1
Sunitinib	increases expression	1
Alitretinoin	decreases expression	1
Acrolein	affects cotreatment, increases expression, increases abundance	1
Arsenic	affects cotreatment, decreases expression, increases abundance, increases expression	1
Benzo(a)pyrene	increases methylation, affects methylation	1
Cisplatin	increases expression	1
Diazinon	increases methylation	1
Fluorouracil	decreases expression	1
Folic Acid	decreases expression	1
Formaldehyde	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL6117360	Binding	Inhibition of full length human FASTK (355 to 444 residues) extracted from Escherichia coli BL21 (DE3) by Malachite Green dye based assay	Thienopyrimidine: A promising scaffold in the development of kinase inhibitors with anticancer activities. — Bioorg Med Chem

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1RZ	Abcam HeLa FASTK KO	Cancer cell line	Female
CVCL_SN18	HAP1 FASTK (-) 1	Cancer cell line	Male
CVCL_SN19	HAP1 FASTK (-) 2	Cancer cell line	Male
CVCL_SN20	HAP1 FASTK (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.